BEVAcizumab / IRINotecan 125 mg

مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

BEVIRI125-02-CN-GY

Ministry of Health

Name:	**File #:**	**Ht (cm):**
Nationality:	**Civil ID:**	**Wt (Kg):**
Gender/Age:	**DOB:**	**BSA (m²):**

Indication(s): Ovarian Cancer / Uterine Cancer / Cervical cancer.
Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; _____

Parameters: Initiate treatment only if ANC ≥ 1000; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min.
Urine dipstick ≤ +2 (If Urine dipstick > 2, Do urine protein/creatine ratio And give bevacizumab If the ratio < 2).
BP ≤ 150/90 mmHg.

Pre-treatment Medications: (30-60 min before starting treatment)

Ondansetron	8 mg PO/IV
Dexamethasone	10 mg PO/IV
Atropine	1 mg SC 30 min before Irinotecan

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
BEVAcizumab (Avastin®)	10 mg/kg	IV in 100 mL NS over 90 min. If the initial infusion is well tolerated, shorten second infusion to 60 min. If the second infusion is well tolerated, shorten the subsequent infusions to 30 min.	D1
IRINotecan	125 mg/m²	IV in 500 mL D5W over 90 min.	D1
To be repeated every 2 weeks until disease progression or intolerable toxicity.			

Special instructions: IRINotecan 125 mg/m² is used for patients taking enzyme inducing drugs and the dose can be increased by 25 mg/m² every 2 weeks up to 340 mg/m² in the absence of toxicity.

Treatment Description:

Cycle	Date	Avastin®	IRINotecan	Physician	Consultant
C# __					
C# __					
C# __					
C# __					
C# __					

Important Notes:

Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological

If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No